{"name":"Kodiak Sciences Inc","slug":"kodiak-sciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":126095000,"netIncome":-176207000,"cash":335578000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KSI-101","genericName":"KSI-101","slug":"ksi-101","indication":"Wet age-related macular degeneration (wAMD)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tabirafusp tedromer","genericName":"Tabirafusp tedromer","slug":"tabirafusp-tedromer","indication":"Allergic asthma","status":"phase_3"}]}],"pipeline":[{"name":"KSI-101","genericName":"KSI-101","slug":"ksi-101","phase":"phase_3","mechanism":"KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.","indications":["Wet age-related macular degeneration (wAMD)","Diabetic retinopathy"],"catalyst":""},{"name":"Tabirafusp tedromer","genericName":"Tabirafusp tedromer","slug":"tabirafusp-tedromer","phase":"phase_3","mechanism":"Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.","indications":["Allergic asthma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbUxNNXpWV0NYNC00bXZyTEgyeXRQMDZwOUxLUzQ1SU9JZXRNYkdSdW9XSW9iZXBxZjRhTGdFU2R2YUsxRmtFd1I3Ym5xWEpGdjlIVVpIYzZaTlhoN3MzZ0lTZUFLWnVLTlN0bUxKVWNSNWRPcE9pblNBZDgxSUN0QUhDN3BPcGxEdWFKaTFFMEJscVJWQkprQjFNWUhCS1hXdDJYZklNRkhxM3p0cFZzWkFZQUhNbVY5UkVkdg?oc=5","date":"2026-04-01","type":"earnings","source":"TradingView","summary":"Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView","headline":"Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYU1xZi1LUlJXeHpTX0lqYVZGeUlFRXFsaFdScDRSZjNWazlZV3BBTUo3VVAwRmlzdVdBS2hQVUtwWGloaWRWSy0zSWFlTHc4dTFqUUotNUJWR3pJejBFN1FTVGdDTWs5aUNra1JZcTdlWHhUb2hadHJLRzNIY0JtRVVURm02WE1QWlUxNER4YVJvRHRxTHpxN0Q0Z3RHSVlzLUh5RGNQQU1kY1dSb21sbEJoa3BLbVptWXM2QjBqNVIySHc?oc=5","date":"2026-03-27","type":"trial","source":"TradingView","summary":"KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - TradingView","headline":"KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYjFrUGdFMkRwZUo1ZnV1VV9OUmhrS3daMHNmbUJoNjg3Z2JVS0tOckJGeklET1d0aDNYNkt5LTQxaGhRU3ozaC1vUml4SWNabWtUNWpMYXBoOGFsTDF4NmpkanhnTmtmOWxWS1JpdW9mT3U5TXczdkRxLUZtVFJ0d3Nfd2JjNkU3LXdyVl9FVk1NelJnQ19Td21uU1JWSk1ZdmUtRlVkZ2o5X0VRRlY4anlxSzZUV3BlWjhwLUQxbDFLQkNncUpTNUl3OXJaZm5Dc2Q2ZFdWMWE?oc=5","date":"2026-03-26","type":"trial","source":"Reuters","summary":"Kodiak Sciences shares soar after eye drug succeeds in late-stage study - Reuters","headline":"Kodiak Sciences shares soar after eye drug succeeds in late-stage study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ0x3MDVfYkdFRjlWNERjUUtaN25jc1ZaUUhBYm5qZ2dwTmRTdmM4ZnhxVGNUeGgybDVFNXZYMVh5Q3BBdFJtN3hha3NiczRJOU5OUi1ONmpDVVpBdEJnWjhHemVXYWJ1Y3hSV0tJTk5rd2MxSWFBZEFSelNKNzFsMl93NGg4X2UweTFzQUI0TXE2cVFnMTJoaG9QS0VZR2sxdWVnMEhra1BYMUpKeXMyMXR3TkVrbGVsOWlzWk11TWIydw?oc=5","date":"2026-03-26","type":"pipeline","source":"Benzinga","summary":"Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga","headline":"Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE14dWdJZXJWREpPU0E5c2Y3YWFVNDZPMmFWYUNRQTRmYW5mV2xLclVBRHFadzcwUm1RQjMxbF93Z1BqMUFUQWg0ZFVaZFFZUVpkYWRNNDFmRlY2SDM4RjZIUFR4Z1F4QXA5MHRzbUNoVHVXQVF6b3QyU005ZExBSHc?oc=5","date":"2025-12-24","type":"pipeline","source":"timothysykes.com","summary":"Kodiak Sciences Stock Surge: An In-Depth Look - timothysykes.com","headline":"Kodiak Sciences Stock Surge: An In-Depth Look","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5ZUk1adDB5WFVFUmxLeWJmdFFpcjJjeHdJRTN3Q2F6bjVMR2RTc0VMTGVjOTlnLVZ1dVhUYUlvOXF3UGNHY1pHZlYtMjVZbWR3dDMwcERHZ19UUnE2WVdXckljWkhKRHJWV0s0bGFXZWNzSVlFWkJCTXYzc18yQ2c?oc=5","date":"2025-12-22","type":"pipeline","source":"Yahoo Finance","summary":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Yahoo Finance","headline":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2025","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOdXNyencxTnRDWmdJV09mWW5uSlc5LVZrUUd6TFZoU3VfNUd0UURxU0Vob3NBaUsyT1pOUV9kb2FxeGZpeVJJbDUtUzRhYkN2Z0tFaUJ0S01sSXoyZUxmektBSkdHZldFRHFvOUc5c3V5WjBudUxna3EzZDNuclY3V28xWkFVZw?oc=5","date":"2025-09-25","type":"trial","source":"Seeking Alpha","summary":"Kodiak stock upgraded at Barclays on Roche data (KOD:NASDAQ) - Seeking Alpha","headline":"Kodiak stock upgraded at Barclays on Roche data (KOD:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPWWVNT25UUzdNalBTTnhMclZPdWUzaWhDWXFZUTBGQ3Rtb0hfRVpCb1c4c3BfcnpNNkUtSzMzM2x4Yi0tTTZqWXNSbm5zclFjRW1vTUU4c3JTSFc5UldmYmRoQjM3aXJPVUVQNG5EaXRWejVxMlhIemFhWEY0N1BRSHpRRXZJREE3TlB4R3RMSnB3Q2xsVVlnd2s4bUNNbXBEUHNuaHdKY3pBdEx4TU1DY013LXNUQTl1WDdOazhYSkJ4TzRh?oc=5","date":"2024-12-10","type":"deal","source":"Contract Pharma","summary":"Nona Biosciences Partners with Kodiak Sciences for Ophthalmic Antibody Discovery - Contract Pharma","headline":"Nona Biosciences Partners with Kodiak Sciences for Ophthalmic Antibody Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQZDdtVmJDR1kybGhzYW1FRWNWcDk1VHI1WGVYczdDSGwzN2c1WVpueHJ4Y2ltZjlScGREaVlwUndmbnRwZmd0QlJTdVJrSzlRemlKUnE1aFNDOTRXbnowbWhYeXhjb3N0cWxKdW1wNXNvQ1JvVGtlVW5UbGh2eU5RM3lEb1BSelZmNVJkZVktVVoxZDJKV3ZnX0t3akg1SUgyYXhxYUMzRTcxUWdpckNQbTBMamRma0E?oc=5","date":"2022-06-10","type":"pipeline","source":"European Pharmaceutical Review","summary":"Lonza and Kodiak open custom-built bioconjugation facility - European Pharmaceutical Review","headline":"Lonza and Kodiak open custom-built bioconjugation facility","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":126095000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-176207000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":335578000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}